Neoleukin Therapeutics, registered in 2018, is a biotechnology company spun out from the University of Washington, focused on the development of protein immunotherapies, using de novo protein design.The company is headquartered in Seattle, WA.In August 2019, Aquinox Pharmaceuticals and Neoleukin Therapeutics entered into a definitive merger agreement under which Aquinox agreed to the acquisition of Neoleukin. Pursuant to the merger agreement, Aquinox would acquire all of the outstanding capital stock of Neoleukin in exchange for the issuance of 4,589,787 newly issued shares of Aquinox common stock, which represented approximately 19.5% of the voting power of Aquinox as of immediately prior to the issuance of such shares, and shares of Aquinox convertible preferred stock convertible into a total of 10,194,838 shares of Aquinox common stock upon receipt of the required approval of the Aquinox stockholders under Nasdaq rules. Following completion of the merger and on an as-converted basis, the former Aquinox